Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.80 |
| ▸ | NPC1 | O15118 | 6/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234810 | 0.92 | NPC1 (0.69) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22103784 | 0.89 | RAB9A (0.76) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10078887 | 0.89 | MEN1 (1.00) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20788543 | 0.88 | NPC1 (0.77) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20791858 | 0.81 | SMN1; SMN2 (0.77) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3790984 | 0.80 | NPC1 (0.66) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5459405 | 0.80 | RAB9A (0.62) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL77497 | 0.79 | NPC1 (0.65) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5459850 | 0.79 | RAB9A (0.64) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL13234609 | 0.79 | KMT2A (0.71) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | RAB9A 4166/4885NPC1 4782/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.